Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-11-07
2006-11-07
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388250, C530S388700, C530S388730, C424S133100, C424S135100, C424S153100, C435S069600, C435S328000, C536S023530
Reexamination Certificate
active
07132510
ABSTRACT:
The present invention is directed to novel peptides and polypeptides that specifically bind to target cells and may have anti-cancer activity, especially blood-related cancers. The present invention includes a peptide or polypeptide comprising an Fv molecule, having a heavy variable chain comprising CDR3, CDR2 and CDR1 regions comprising the amino acid sequences SEQ ID NOS:8, 115 and 114, respectively.
REFERENCES:
patent: 5168062 (1992-12-01), Stinski
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5385839 (1995-01-01), Stinski
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5427908 (1995-06-01), Dower et al.
patent: 5432018 (1995-07-01), Dower et al.
patent: 5659018 (1997-08-01), Berndt et al.
patent: 5716836 (1998-02-01), Suiko
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5763215 (1998-06-01), Blumberg et al.
patent: 5795776 (1998-08-01), Fischer
patent: 5821337 (1998-10-01), Carter et al.
patent: 5827817 (1998-10-01), Larsen et al.
patent: 5843439 (1998-12-01), Anderson et al.
patent: 5945304 (1999-08-01), Fischer
patent: 6124267 (2000-09-01), McEver et al.
patent: 6132730 (2000-10-01), Thorpe et al.
patent: 6312694 (2001-11-01), Thorpe et al.
patent: 6548636 (2003-04-01), Dragie et al.
patent: 6593459 (2003-07-01), Cummings et al.
patent: 2002/0058034 (2002-05-01), Manjunath et al.
patent: 2003/0064410 (2003-04-01), Hubbell et al.
patent: 0 589 877 (1996-11-01), None
patent: WO 93/11778 (1993-06-01), None
patent: WO 94/26787 (1994-11-01), None
patent: WO97/02479 (1997-01-01), None
patent: WO 98/12318 (1998-03-01), None
patent: WO 00/29004 (2000-05-01), None
Paul W. E. Fundamental Immunology, 3rdedition, 1993, pp. 292-295.
Altschul et al. “Gapped Blast and PSI-Blast: a new generation of protein database search programs”, Nucleic Acids Research, 1997, vol. 25, No. 17, pp. 3389-3402.
Bass, et al. “Hormone Phage: An enrichment method for variant proteins with altered binding properties”, Protein Structure, Function and Genetics, 1990 vol. 8, pp. 309-314.
Caron et al., “Murine and Humanized Constructs of Monoclonal Antibody M195 (Anti-CD33) for the therapy of acute myelogenous leukemia”, Cancer Supplement, Feb. 1, 1994, vol. 73, No. 3, pp. 1049-1056.
Caron et al., “A Phase 1B trial of humanized monoclonal antibody M195 (Anti-CD33) in myeloid leukemia: specific targeting without immunogenicity”.
Cwirla et al., “Peptides on phage: a vast library of peptides for identifying ligands”, Proc. Nat'l. Acad. Sci. USA, Aug. 1990, vol. 87, pp. 6378-6382.
Devlin et al., “Random peptide libraries: a source of specific protein binding molecules”, Science, vol. 249, pp. 404-406.
Griffiths et al., “Isolation of high affinity human antibodies directly from large synthetic repertoires,” EMBO Journal, 1994, vol. 13, No. 14, pp. 3245-3260.
Henkart, “Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules”, Immunity, Aug. 1984, vol. 1, pp. 343-346.
Holliger et al., ““Diabodies”: small bivalent and bispecific antibody fragments”, Proc. Nat'l. Acad. Sci, USA, Jul. 1993, vol. 90, pp. 6444-6448.
Hudson et al., “High avidity scFv multimers: diabodies and triabodies”, Journal of Immun. Methods, 1999, vol. 231, pp. 177-189.
Jarvik et al., “Epitope Tagging”, Annu. Rev. Genet., 1998, vol. 32, pp. 601-618.
Jurcic et al., ABSTRACT #2528, Blood, 1992 (10 Suppl. Part 1-2).
Kortt et al., “Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer”, Protein Engineering, 1997, vol. 10, No. 4, pp. 423-433.
McCafferty et al., “Phage antibodies: filamentous phage displaying antibody variable domains”, Nature, Dec. 6, 1990, vol. 348, pp. 552-554.
McGraw et al., “Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias”, Cancer Immunol. Immunotherapy, 1994, vol. 39, pp. 367-374.
Nissim et al., “Antibody fragments from a ‘single pot’ phage display library as immunochemical reagents”, EMBO Journal, 1994, vol. 13, No. 3, pp. 692-698.
Scott et al., “Searching for peptide ligands with an epitope library”, Science, Jul. 27, 1990, vol. 249, pp. 386-390.
Sgouros et al. ABSTRACT #979, J. Nucl. Med. vol. 38 (5 Suppl.).
Sievers et al., ABSTRACT #2246, Blood, vol. 90 (10 Suppl. 1 Part 1).
Smith, “Filamentous Fusion Phage: Novel expression vectors that displayed cloned antigens on the virion surface”, Science, Jun. 14, 1985, vol. 228, pp. 1315-1317.
Squier et al., “Cell-mediated cytotoxic mechanisms”, Current Opinion in Immunology, 1994, vol. 6, pp. 447-452.
Sun et al., “Antitumour activity of a chimeric antibody against the leucocyte antigen CD48”, Cancer Immunol. Immunotherapy, 2000, vol. 48, pp. 595-602.
Takebe et al., “Srα Promoter: an efficient and versatile mammalian cDNA Expression System . . . ”, Molecular and Cellular Biology, Jan. 1988, vol. 8, No. 1, pp. 466-472.
Thompson et al. “A fully human antibody neutralising biologically active human TGFβ2 for use in therapy”, J. of Immunol. Methods, 1999, vol. 227, pp. 17-26.
Tomlinson et al., The repertoire of human germline VHsegments with different hypervariable loops, J. Mol. Biol., 1992, vol. 227, pp. 776-798.
Adams, G.P. et al., “Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2
eu,” British Journal of Cancer (1998) vol. 77, No. 9, pp. 1405-1412.
Afshar-Kharghan, Vahid et al., “Human polymorphism of P-selectin glycoprotein ligand 1 attributable to variable numbers of tandem decameric repeats in the mucinlike region,” Blood, vol. 97, No. 10, May 15, 2001, pp. 3306-3307.
Altman, John D. et al., “Phenotypic Analysis of Antigen-Specific T Lymphocytes,” Science, vol. 274, Oct. 4, 1996, pp. 94-96.
Bundgaard, Jens R. et al., “New Consensus Features for Tyrosine O-Sulfation Determined by Mutational Analysis,” The Journal of Biological Chemistry, vol. 272, No. 35, Aug. 29, 1997, pp. 21700-21705.
Clezardin, Philippe et al., “Role of Platelet Membrane Glycoproteins Ib/Ix and Iib/IIIa, and of Platelet α-Granule Proteins in Platelet Aggregation Induced by Human Osteosarcoma Cells,” Cancer Research, vol. 53, Oct. 1, 1993, pp. 4695-4700.
Cochran, Jennifer R. et al., “The Relationship of MHC-Peptide Binding and T Cell Activation Probed Using Chemically Defined MHC Class II Oligomers,” Immunity, vol. 12, Mar. 2000, pp. 241-250.
de Kruif, John et al., “Leucine Zipper Dimerized Bivalent and Bispecific scFv Antibodies from a Semi-synthetic Antibody Phage Display Library,” The Journal of Biological Chemistry, vol. 271, No. 13, Mar. 29, 1996, pp. 7630-7634.
Gasic, Gabriel J. et al., “Antimetastatic Effects Associated with Platelet Reduction,” Proc. Natl. Acad. Sci. USA, vol. 61, 1968, pp. 46-52.
Gilbert, Walker et al., “The LAC Operator is DNA,” Proc. Natl. Acad. Sci. USA, vol. 58, 1967, p. 2415-2421.
Harrison, Jacqueline L. et al., “Screening of Phage Antibody Libraries,” Methods in Enzymology, vol. 267, 1996, pp. 83-109.
Roberts, Jeffrey W. et al., “Lysogenic Induction,” Lambda II, Cold Spring Harbor Laboratory, 1983, pp. 123-144.
Hudson, Peter J. et al., “Recombinant antibody constructs in cancer therapy,” Current Opinion in Immunology, vol. 11, 1999, pp. 548-557.
Jurcic, J.G. et al., “Targeted alpha-particle therapy for myeloid leukemias: A phase I trial of bismuth-213-HuM195 (anti-CD33),” Blood, 90(suppl.): 504a, 1997.
Kamiyama, Mikio et al., “Inhibition of Human Platelet Glycoprotein IIB/IIIA Binding to Fibrinogen by Tumor Cell Membrane Ptoreins,” Cancer Research, vol. 53, Jan. 15, 1993, pp. 221-223.
Karpatkin, S. et al., “
Guy Rachel
Hagay Yocheved
Lazarovits Janette
Levanon Avigdor
Lifshitz Orly
Bio-Technology General (Israel) Ltd.
Blanchard David J.
Helms Larry R.
Kenyon & Kenyon LLP
LandOfFree
Specific human antibodies for selective cancer therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Specific human antibodies for selective cancer therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Specific human antibodies for selective cancer therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3680492